Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study
Corresponding Author
Hanny Al-Samkari
Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA
Boston Hemophilia Center, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Correspondence
Hanny Al-Samkari, Division of Hematology, Massachusetts General Hospital, Zero Emerson Place Suite 118 Office 112, Boston, MA 02114, USA.
Email: [email protected]
Search for more papers by this authorStacy E. Croteau
Boston Hemophilia Center, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Hanny Al-Samkari
Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA
Boston Hemophilia Center, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Correspondence
Hanny Al-Samkari, Division of Hematology, Massachusetts General Hospital, Zero Emerson Place Suite 118 Office 112, Boston, MA 02114, USA.
Email: [email protected]
Search for more papers by this authorStacy E. Croteau
Boston Hemophilia Center, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
Search for more papers by this author
Supporting Information
| Filename | Description |
|---|---|
| hae14140-sup-0001-DataS1.docxWord document, 29.7 KB | Data S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematol Am Soc Hematol Educ Program. 2002; 1-9.https://pubmed.ncbi.nlm.nih.gov/12446416/
- 2Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9): 809-818.
- 3Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018; 379(9): 811-822.
- 4Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019; 25(1): 33-44.
- 5Skinner M, Negrier C, Paz-Priel I, et al. Emicizumab Prophylaxis Improves Long-term Physical Health Scores in Persons with Haemophilia A (PwHA) with and without Inhibitors: Update from the HAVEN 3 and HAVEN 4 Studies. Res Pract Thromb Haemost. 2019; 3(S1): 698.
- 6Al-Samkari H, Croteau SE. Shifting landscape of hemophilia therapy: implications for current clinical laboratory coagulation assays. Am J Hematol. 2018; 93: 1082-1090.
- 7Draugalis JR, Coons SJ, Plaza CM. Best practices for survey research reports: a synopsis for authors and reviewers. Am J Pharm Educ. 2008; 72(1): 11.
Citing Literature
